AKTS (Aktis Oncology) Common Stock: $0.01 Mil (As of Mar. 2026)


AKTS Aktis Oncology Inc AKTS
9 GF Score
Price $28.91
! 3 Warning Signs
View Full Analysis

What is Aktis Oncology Common Stock?

Aktis Oncology AKTS +0.77% 9 Common Stock is $0.01 Mil as of Mar. 2026. GuruFocus rates AKTS with a GF Score™ of 9/100. The stock has 3 warning signs investors should review.

Aktis Oncology's quarterly common stock stayed the same from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($0.00 Mil) but then increased from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.01 Mil).

Aktis Oncology Common Stock Historical Data

* Premium members only.

The historical data trend for Aktis Oncology's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aktis Oncology Common Stock Chart

Aktis Oncology Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Common Stock
0.00 0.00 0.00 0.00

Aktis Oncology Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.01
AKTS
9GF Score
Aktis Oncology Inc AKTS
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aktis Oncology Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.01 Mil mean?
Aktis Oncology (AKTS) has a Common Stock of $0.01 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Aktis Oncology and its competitors.
Is Aktis Oncology's Common Stock too high?
Aktis Oncology's current Common Stock is $0.01 Mil. Overall, Aktis Oncology has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's Common Stock compare to ZBIO and MLTX?
Aktis Oncology's Common Stock of $0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Aktis Oncology and its competitors. Aktis Oncology's current Common Stock is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current Common Stock of $0.01 Mil. The current Common Stock is $0.01 Mil. Aktis Oncology's overall GF Score™ is 9/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current Common Stock is $0.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aktis Oncology Business Description

Address 17 Drydock Avenue, Suite 17-401, Boston, MA, USA, 02210
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
9GF Score

Get the complete analysis for AKTS

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.91
Price